Biomea Fusion (BMEA)

Biomea Fusion Stock Analysis & Ratings

BMEA Stock Chart & Stats

Day’s Range$5.79 - $6.56
52-Week Range$2.84 - $21.48
Previous Close$6.03
Average Volume (3M)150.79K
Market Cap$190.76M
P/E Ratio-4.6
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-1.42



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $2.84 and its highest was $21.48 in the past 12 months.
    What is Biomea Fusion’s market cap?
    Biomea Fusion’s market cap is $190.76M.
      What is Biomea Fusion’s price target?
      The average price target for Biomea Fusion is $19.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $25.00 ,the lowest forecast is $13.00. The average price target represents 190.52% Increase from the current price of $6.54.
        What do analysts say about Biomea Fusion?
        Biomea Fusion’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Biomea Fusion’s upcoming earnings report date?
          Biomea Fusion’s upcoming earnings report date is Aug 10, 2022 which is in 79 days.
            How were Biomea Fusion’s earnings last quarter?
            Biomea Fusion released its earnings results on May 16, 2022. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.526 by -$0.034.
              Is Biomea Fusion overvalued?
              According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
                Does Biomea Fusion pay dividends?
                Biomea Fusion does not currently pay dividends.
                What is Biomea Fusion’s EPS estimate?
                Biomea Fusion’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Biomea Fusion have?
                Biomea Fusion has 29,170,000 shares outstanding.
                  What happened to Biomea Fusion’s price movement after its last earnings report?
                  Biomea Fusion reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.526. Following the earnings report the stock price went up 0.518%.
                    Which hedge fund is a major shareholder of Biomea Fusion?
                    Among the largest hedge funds holding Biomea Fusion’s share is RA Capital Management. It holds Biomea Fusion’s shares valued at 2M.


                      Biomea Fusion Stock Analysis

                      The Biomea Fusion stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Biomea Fusion

                      Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis